EORTC 22863 is a randomized phase III trial assessing the benefit of the addition of long-term androgen suppression with a GnRH analogues (the authors used goserelin for this study) to external irradiation in patients with prostate cancer with high metastatic risk (10-year follow-up) [26]. This evidence concerns the gene GNRH1 and Familial prostate cancer.